Mesothelioma is extremely difficult to diagnose, and a missed diagnosis can lead to deadly delays in treatment. But just as it’s important to correctly and quickly identify the rare, asbestos-related disease, patients with symptoms of mesothelioma need to work with experienced professionals to ensure that they don’t have some other, dangerous condition. A newly published
Biopsy is one of the most essential tools for diagnosing mesothelioma, but some patients have conditions that put the procedure out of reach. Weakened condition and severe adhesions can make biopsy’s accompanying general anesthesia too dangerous, leaving patients with uncertainty and unclear treatment paths. According to a new case report published in Respirology Case Reports,
In addition to being one of the most challenging cancers to treat, mesothelioma is one of the hardest cancers to catch early. It can take 40 or more years after asbestos exposure for symptoms like shortness of breath or fluid buildup around the lungs to appear, and by then, the disease is often too far
For many patients suspected of having mesothelioma, confirming the diagnosis is complicated by their physical condition: Undergoing general anesthesia or conventional thoracoscopy is just too risky. Recently, Japanese researchers reported successfully diagnosing the rare form of cancer using pleural cryobiopsy under local anesthesia. This represents a valuable alternative and potentially quicker path to appropriate treatment.
Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) and Pressurized Intra-Thoracic Aerosol Chemotherapy (PITAC) are both innovative new techniques that deliver chemotherapy medications in the form of a pressurized mist that’s sprayed directly into the abdominal or chest cavity. These minimally invasive procedures have introduced new treatment options for patients diagnosed with peritoneal or pleural mesothelioma who have
A new study by physicians at Leiden University Medical Center in the Netherlands is helping doctors better understand how scar tissue formed during mesothelioma treatment affects whether surgery is possible and how well it works. These findings could help doctors better choose the right patients for surgery and improve patient outcomes.
In what is a first in North America, Northern California’s Stanford Medicine has announced that thoracic surgeon Dr. Leah Backhus performed the first PITAC procedure for mesothelioma. The groundbreaking minimally invasive operation offers real hope for patients who are not candidates for more aggressive surgery.
Mesothelioma is one of the most aggressive, most deadly forms of cancer, and researchers around the world have dedicated themselves to finding a way to improve outcomes for those impacted by this asbestos-related disease. Recently, the University College London (UCL) and University College London Hospitals NHS Foundation Trust announced that they will be conducting a
A new analysis revealing startling per capita asbestos consumption rates in Central Asia raises significant concerns about future mesothelioma diagnoses. The most impacted nations are Uzbekistan, which in 2023 was using 3.4 kilograms per person annually, and Tajikistan, where consumption was equivalent to 2.34 kilograms per capita in 2023. The dramatic increase in usage in
Immune checkpoint inhibitors are a type of immunotherapy that has changed the way doctors treat mesothelioma. These drugs work by helping the immune system recognize and attack cancer cells that would otherwise go undetected. For patients with pleural mesothelioma that cannot be removed with surgery, immune checkpoint inhibitors have become a standard first-line treatment option